Search research articles
Contact Us
Filters
Showing results (341-350 of 355) with videos related to
Page
of 36
Sort By:
Cancer
|
January 18, 2024
Adjuvant platinum versus capecitabine for residual, invasive, triple-negative breast cancer: Patient-reported outcomes in ECOG-ACRIN EA1131
Karen L Smith, Fengmin Zhao, Ingrid A Mayer, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
August 19, 2015
Cancer-Related Fatigue, Version 2.2015
Ann M Berger, Kathi Mooney, Amy Alvarez-Perez, et al.
JCO Oncology Practice
|
April 28, 2026
Engendering Reproductive Health Within Oncologic Survivorship Trial, ECOG-ACRIN E1Q11
Ashlesha A Patel, Ju-Whei Lee, Howard A Zaren, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
February 16, 2013
Distress management
Jimmie C Holland, Barbara Andersen, William S Breitbart, et al.
JAMA Oncology
|
October 1, 2019
Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial
Joseph A Sparano, Robert J Gray, Della F Makower, et al.
The Oncologist
|
December 20, 2019
Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil, and Leucovorin Versus Oxaliplatin, 5-Fluorouracil, Leucovorin, and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Preoperative Chemoradiation: A Trial of the ECOG-ACRIN Research Group (E5204)
A Bapsi Chakravarthy, Fengmin Zhao, Neal J Meropol, et al.
Journal of the National Cancer Institute
|
September 28, 2020
Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx Trial
Kathy S Albain, Robert J Gray, Della F Makower, et al.
JCO Oncology Advances
|
May 18, 2026
Impact of Race, Socioeconomic Status, and Clinicopathologic Features on Clinical Outcomes in Triple-Negative Breast Cancer in the ECOG-ACRIN EA1131 Trial
Moriah Forster, Fengmin Zhao, Sarah Bell, et al.
The New England Journal of Medicine
|
June 4, 2019
Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer
Joseph A Sparano, Robert J Gray, Peter M Ravdin, et al.
Theranostics
|
August 22, 2017
Mutational Landscapes of Smoking-Related Cancers in Caucasians and African Americans: Precision Oncology Perspectives at Wake Forest Baptist Comprehensive Cancer Center
Ville Kytola, Umit Topaloglu, Lance D Miller, et al.
Page
of 36
Search research articles
Search
Showing results (341-350 of 355) with videos related to
Sort By:
Page
of 36
Cancer
|
January 18, 2024
Adjuvant platinum versus capecitabine for residual, invasive, triple-negative breast cancer: Patient-reported outcomes in ECOG-ACRIN EA1131
Karen L Smith, Fengmin Zhao, Ingrid A Mayer, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
August 19, 2015
Cancer-Related Fatigue, Version 2.2015
Ann M Berger, Kathi Mooney, Amy Alvarez-Perez, et al.
JCO Oncology Practice
|
April 28, 2026
Engendering Reproductive Health Within Oncologic Survivorship Trial, ECOG-ACRIN E1Q11
Ashlesha A Patel, Ju-Whei Lee, Howard A Zaren, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
February 16, 2013
Distress management
Jimmie C Holland, Barbara Andersen, William S Breitbart, et al.
JAMA Oncology
|
October 1, 2019
Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial
Joseph A Sparano, Robert J Gray, Della F Makower, et al.
The Oncologist
|
December 20, 2019
Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil, and Leucovorin Versus Oxaliplatin, 5-Fluorouracil, Leucovorin, and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Preoperative Chemoradiation: A Trial of the ECOG-ACRIN Research Group (E5204)
A Bapsi Chakravarthy, Fengmin Zhao, Neal J Meropol, et al.
Journal of the National Cancer Institute
|
September 28, 2020
Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx Trial
Kathy S Albain, Robert J Gray, Della F Makower, et al.
JCO Oncology Advances
|
May 18, 2026
Impact of Race, Socioeconomic Status, and Clinicopathologic Features on Clinical Outcomes in Triple-Negative Breast Cancer in the ECOG-ACRIN EA1131 Trial
Moriah Forster, Fengmin Zhao, Sarah Bell, et al.
The New England Journal of Medicine
|
June 4, 2019
Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer
Joseph A Sparano, Robert J Gray, Peter M Ravdin, et al.
Theranostics
|
August 22, 2017
Mutational Landscapes of Smoking-Related Cancers in Caucasians and African Americans: Precision Oncology Perspectives at Wake Forest Baptist Comprehensive Cancer Center
Ville Kytola, Umit Topaloglu, Lance D Miller, et al.
Page
of 36